Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-UMIN000058660) titled 'Real-world Outcomes in Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL) Treated with Epcoritamab in Japan' on Aug. 1.
Study Type: Observational
Study Design:
Not selected Not selected
Primary Sponsor: Genmab US, Inc.
Condition:
Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Recruitment Status: Not Recruiting
Phase: Not selected
Date of First Enrollment: 2025/08/16
Target Sample Size: 300
Countries of Recruitment:
Japan
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066647
Published by HT Digital Content Services with permi...